Biotech Stocks Facing FDA Decision In February 2023

1 / 10

In the month of January, the FDA approved only two novel drugs – Leqembi and Brenzavvy - compared to 4 in the same month last year.

Leqembi, for the treatment of Alzheimer's disease, was granted accelerated approval on January 6.

Brenzavvy, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, was approved on January 23.